SJURVM schreef op 21 augustus 2016 16:35:
$1.9m/month means roughly that here is cash in the kitty until May 2017.
MDXH hopes obviously for a better revenue recognition in H2 i.e. make people actually pay. There was $20m in "unrecognized" revenue for FY2015, so if this can be turned into hard cash there might not be an immediate need for a cash raising exercise.
However, it is always better to look at the "worst" case scenario.
The question is how much would MDXH actually need to raise? and in what form? Bank loan or equity issue? If Equity issue, from exisitng shareholders orfrom new shareholders i.e Nasdaq?
If MDXH can see,realistically, that it will be cash positive generative during 2017/early 2018 then a short term loan might be sufficient.
If MDXh believes it might need a little longer then maybe an equity issue is in order.
Could Valiance atually come up with the cash?
Or do you go for the american investor who is more "risk" taker than his counterpart in Europe? if yes, then Nasdaq or private placement? and for how much?
Or is it that by 2017 the exisitng shareholders will want to sell to the highest bidder (with cash in the bank)?
I think someone mentioned Biocartis and the new chairman is also on Biocartis board.
Would Exact be interested?
How much did Valiance,Biovest and Alychlo actually pay for their stake? and how much would they want to sell their %?